The way these pharmacies have assumed a well known position in this projected $one hundred billion industry—supplying providers with medications, like oral GLP-1s, that are not FDA-permitted—warrants closer analyze. These seemed like complex functions, providing reductions on bulk purchases and in many cases looking to upsell the investi